他汀类药物和pcsk9抑制剂有多大益处?

Richard M Fleming
{"title":"他汀类药物和pcsk9抑制剂有多大益处?","authors":"Richard M Fleming","doi":"10.32474/sjfn.2019.02.000136","DOIUrl":null,"url":null,"abstract":"Cholesterol is a combination of cholesterol, protein and fat, assembled in different combinations, yielding various forms of cholesterol molecules. Routine evaluation of one’s risk for coronary artery disease has focused on measuring cholesterol levels in the blood. Assessment of the benefit of lowering LDL cholesterol has focused on the use of these blood tests, coronary arteriograms and Coronary Artery Calcium (CAC) scores. However, evidence demonstrates that changes in blood cholesterol and other inflammatory markers does not correlate with actual changes in physiologic CAD. The use of most cholesterol lowering medications is not associated with a reduction in body LDL cholesterol, but rather a shift of LDL from the blood into the cells of the body, where actual oxidative damage is associated with inflammatory problems. Absent the demonstration of improvement in physiologic CAD, coupled with increased questions about benefit to risk ratios, the true benefit of these drugs should be transparently reviewed along with a call for more investigation into the impact of the dietary issues related to CAD.","PeriodicalId":191049,"journal":{"name":"Scholarly Journal of Food and Nutrition","volume":"9 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2019-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"How Beneficial are Statins and PCSK9-Inhibitors?\",\"authors\":\"Richard M Fleming\",\"doi\":\"10.32474/sjfn.2019.02.000136\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Cholesterol is a combination of cholesterol, protein and fat, assembled in different combinations, yielding various forms of cholesterol molecules. Routine evaluation of one’s risk for coronary artery disease has focused on measuring cholesterol levels in the blood. Assessment of the benefit of lowering LDL cholesterol has focused on the use of these blood tests, coronary arteriograms and Coronary Artery Calcium (CAC) scores. However, evidence demonstrates that changes in blood cholesterol and other inflammatory markers does not correlate with actual changes in physiologic CAD. The use of most cholesterol lowering medications is not associated with a reduction in body LDL cholesterol, but rather a shift of LDL from the blood into the cells of the body, where actual oxidative damage is associated with inflammatory problems. Absent the demonstration of improvement in physiologic CAD, coupled with increased questions about benefit to risk ratios, the true benefit of these drugs should be transparently reviewed along with a call for more investigation into the impact of the dietary issues related to CAD.\",\"PeriodicalId\":191049,\"journal\":{\"name\":\"Scholarly Journal of Food and Nutrition\",\"volume\":\"9 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-10-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Scholarly Journal of Food and Nutrition\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.32474/sjfn.2019.02.000136\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Scholarly Journal of Food and Nutrition","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32474/sjfn.2019.02.000136","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

摘要

胆固醇是胆固醇、蛋白质和脂肪的组合,以不同的组合方式组合,产生各种形式的胆固醇分子。对冠状动脉疾病风险的常规评估主要集中在测量血液中的胆固醇水平。对降低低密度脂蛋白胆固醇的益处的评估主要集中在这些血液检查、冠状动脉造影和冠状动脉钙(CAC)评分的使用上。然而,有证据表明,血胆固醇和其他炎症标志物的变化与生理性CAD的实际变化无关。大多数降胆固醇药物的使用与体内低密度脂蛋白胆固醇的降低无关,而是将低密度脂蛋白从血液转移到身体细胞中,在那里实际的氧化损伤与炎症问题有关。缺乏对生理性冠心病改善的证明,再加上对获益风险比的质疑增加,这些药物的真正益处应该被透明地审查,同时呼吁对与冠心病相关的饮食问题的影响进行更多的调查。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
How Beneficial are Statins and PCSK9-Inhibitors?
Cholesterol is a combination of cholesterol, protein and fat, assembled in different combinations, yielding various forms of cholesterol molecules. Routine evaluation of one’s risk for coronary artery disease has focused on measuring cholesterol levels in the blood. Assessment of the benefit of lowering LDL cholesterol has focused on the use of these blood tests, coronary arteriograms and Coronary Artery Calcium (CAC) scores. However, evidence demonstrates that changes in blood cholesterol and other inflammatory markers does not correlate with actual changes in physiologic CAD. The use of most cholesterol lowering medications is not associated with a reduction in body LDL cholesterol, but rather a shift of LDL from the blood into the cells of the body, where actual oxidative damage is associated with inflammatory problems. Absent the demonstration of improvement in physiologic CAD, coupled with increased questions about benefit to risk ratios, the true benefit of these drugs should be transparently reviewed along with a call for more investigation into the impact of the dietary issues related to CAD.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信